Introduction
Several radioactive isotopes of iodine (e.g. I-129, I-131, I-133) are generated in large amounts as a by-product of uranium fission, which is primarily used in nuclear reactors for energy production. In the event of a nuclear reactor accident and when radioactive material is released to the atmosphere, radioactive isotopes of iodine may be incorporated into the human body through inhalation or ingestion of contaminated food and milk (Braverman et al 2014) . I-131 with a half-life of 8 d is particularly relevant because of its potential to concentrate in the thyroid gland (Reiners and Schneider 2013) . When inhaled, about 10%-30% of the radioactive iodine I-131 will primarily accumulate in the thyroid, while the remaining amount will be discharged from the body with the urine (Yoshida et al 2014) . As part of I-131's decay process, beta-radiation is emitted and affects the thyroid and its surrounding tissue, and may lead to adverse health outcomes such as thyroid dysfunctions and thyroid cancer.
From the Life Span study, there is evidence for the development of benign and malignant thyroid nodules as a result of external exposure to ionizing radiation among the atomic bomb survivors (e.g. Preston et al 2007) . Following the Chernobyl reactor accident, which involved a large release of I-131 into the environment, significantly increased numbers of thyroid cancer and thyroid dysfunction such as hypothyroidism were observed in individuals from highly contaminated regions in Ukraine and Belarus (Kazakov et al 1992 , Likhtarev et al 1995 , Heidenreich et al 1999 . Regarding thyroid cancer, a study from Belarus suggests that incidence rates between 1970 and 2001 increased from 0.4 per 100 000 to 3.5 per 100 000 among males and from 0.8 per 100 000 to 16.2 per 100 000 among females, with higher relative increases in high compared to lower exposure areas of Belarus (Mahoney et al 2004) .
In addition, children and adolescents have been found to be at higher risk for developing thyroid diseases compared to adults. This is due to their smaller thyroid gland, its development during childhood and adolescence which leads to a 5-10 fold increase of committed thyroid dose, higher uptake of radioiodine, and higher sensitivity to radioiodine release of the organs, tissues and cells (Klugbauer et al 1995 , Shakhtarin et al 2003 , Cardis et al 2005 . Furthermore, it is suggested that radiation exposure during the prenatal phase is associated with an increased risk of thyroid cancer (Hatch et al 2009) , and I-131 transmission from mother to infant during breastfeeding has been investigated as an additional risk factor for infants to develop thyroid cancer in later stages in life (Miller and Zanzonico 2005, Schneider and Smith 2012) . In contrast, radiation-induced thyroid cancer risk for adults is thought to be very low and may be close to zero (Thompson et al 1994) . Hypothyroidism is considered a potential outcome associated with ionizing radiation exposure caused by immediate cell killing after high radiation doses or as the late effect of lower doses, for example through the induction of autoimmune disease (Ron and Brenner 2010) .
The oral administration of potassium iodide (KI) is assumed to be the most effective and preventive radiation protection measure to reduce the risk of adverse health outcomes for the exposed population in the event of an accidental release of any isotopes of radioactive iodine (Le Guen et al 2007 , Jang et al 2008b . KI is essentially thought to saturate the iodide transport mechanism of the thyroid by inhibiting the intrathyroid organification of iodide (acute Wolff-Chaikoff effect), by dilution and by promoting excretion and thus, reducing the amount of committed dose to the thyroid gland, its surrounding tissue, and the body (Sternthal et al 1980 , Becker 1983 , Adelstein 1991 .
The suggested KI administration dose depends on the predicted exposure levels to the thyroid of the defined population groups (i.e. intervention/action levels) (WHO 1999 , European Commission 2010 . The suggested KI doses further vary to account for the respective risks of vulnerable population groups (newborn, children and adolescents, and pregnant and lactating women). The effective blocking of the thyroid is thought to be achieved with a dose of 130-170 mg of KI (Federal Drug Administration 2001 , European Commission 2010 . Fractions of these quantities are suggested to be used in specific population groups (1 in adults and adolescents in addition to pregnant and lactating women, if necessary; 1/2 in children; 1/4 in infants; 1/8 in newborns) (WHO 1999 , Federal Drug Administration 2001 . Although KI administration blocks the thyroid gland, it does not provide complete protection from accumulating radioactive iodine. A single dose of KI approximately blocks the thyroid for between 24 and 36 h but the blocking capacity decreases with increased time after administration (Federal Drug Administration 2001 , European Commission 2010 . In the event of the continuous release of I-131, repeated administration may be required to ensure prolonged protection of the general population as the speculated protective effect of one KI dose is thought to decrease with time (WHO 1999) .
The Polish government initiated KI administration in the Polish general population, in part icular in children and adolescents, in late April and early May 1986 as a consequence of the reactor accident in Chernobyl and the subsequent discharge of radioactive iodine to the environ ment. Assessing the efficacy of KI administration, Nauman and Wolff (1993) estimated a reduction in committed thyroid dose between 40% and 62% for those children who were administered KI one to four days after the start of exposure. With regard to the timing of the intervention, a simulation study demonstrated higher protective KI efficacy when its administration is carried out in early exposure stages (78.9% versus 39.1% with KI given within 2 h or at 8 h after uptake of radioactive iodine, respectively) (Jang et al 2008a) . It is notable that in Poland, where immediate thyroid blocking measures using KI solution were implemented within the first 4 d after the start of the exposure, about 90% of the children under the age of 16 showed thyroid dose commitments below the predicted mean maximal burden (<50 mSv) in this risk group (Nauman and Wolff 1993) .
A recent systematic review further examined the adverse side effects of KI administration to block the thyroid (Spallek et al 2012) . The evidence gathered suggested that even the administration of comparatively high doses of KI did not result in serious adverse health outcomes in the exposed population groups. Severe reactions of clinical significance were rare and in particular observed in individuals with pre-existing thyroid disorders and iodine sensitivity. There was little data available on age differences. The review results, however, suggested that newborns and the elderly may experience more adverse side effects after KI administration compared to other age groups (Spallek et al 2012) . Overall, the evidence-base was relatively weak, because with the exception of the Polish study by Nauman and Wolff (1993) most studies on the effects of KI were primarily set in the clinical context and addressed exposure reduction as part of therapy procedures, with comparatively high organ doses. KI administration is endorsed by the 1999 WHO's Guidelines for Iodine Prophylaxis following Nuclear Accidents (WHO 1999) and is also widely implemented in most national guidelines (Federal Drug Administration 2001 , National Radiological Protection Board 2001 , European Commission 2010 . To date, the current guidelines are primarily based on expert opinion, but the scientific base has not been reviewed systematically.
As part of the update of the existing WHO guideline from 1999 (WHO 1999) , present WHO regulations for guidelines development require a systematic review of the scientific evidence in order to inform the updating process (WHO 2014). Thus, the present project aims to provide an up-to-date review on the efficacy of KI administration to reduce adverse health outcomes such as thyroid dysfunctions and thyroid cancer for the general population in the event of an accidental release of radioactive iodine to the environment.
We aimed to assess the effects of KI administration on thyroid cancer, hypothyroidism, and benign thyroid nodules in a population exposed to radioiodine release. Specifically, we wanted to
• assess whether specific population groups (e.g. children and adolescents between 0 and 18 years of age, pregnant or lactating women) are differentially affected by KI administration • identify appropriate timing • assess whether repeated KI administration may be warranted in circumstances of repeated/continuous exposure to reduce the accumulation of I-131 in the thyroid gland in the exposed population compared to no intervention.
The study's objective was based on the following specific question, formulated in the PICO (population, intervention, comparison, outcome) style:
In a population exposed to radioiodine release (P), does the administration of KI for prophylaxis (I) versus no administration of KI (C) affect the risk of relevant outcomes, including thyroid cancer, hypothyroidism, and benign thyroid nodules (O)?
Two sub-PICOs on the issue of the timing of KI administration and on repeat administration in the case of continuous release of radionuclides were also formulated, but are not reported in depth here as no evidence was found.
Methods

Criteria for considering studies for this review
The review covered a broad spectrum of study types, including randomized and non-randomized studies (RCTs, Quasi-RCTs, controlled before-after studies, time-series analysis, cohort studies, case-control studies, surveys, e.g. pharmaco-epidemiological studies). Individuals who were exposed to external ionizing radiation or radioactive iodine in the environment (including the general population and workers) were considered. Stable oral iodine/KI administration, irrespective of the dosing or timing, were considered as interventions, and no oral iodine/KI administration as an eligible comparison. Studies that report on thyroid cancer, hypothyroidism, benign thyroid nodules, and mortality from thyroid cancer as outcome measures were included in this review.
Search methods for identification of studies
MEDLINE (via PubMed) and Excerpta Medica database (EMBASE) were searched using detailed, database-specific searches using a broad set of relevant keywords and terms. The search strategy was applied with additional keywords for possible comparators and without the use of filters for study types to improve the results of the literature search with respect to the total number of relevant studies. The literature search was limited to evidence from studies in humans. Databases, as listed above, were searched on 16 June 2015. All reference lists of relevant records were searched by hand for additional relevant studies. For details on the MEDLINE and EMBASE search strategies, see appendices A and B, respectively.
A review advisory group of experts supported the planning for the literature search and provided feedback on the research questions, the search strategy and the selected databases as well as on the review results.
Data collection and analysis
A research librarian assisted with conducting the database search for relevant studies (LC). First, studies' titles and abstracts, if feasible, as identified by the search were reviewed by two authors in duplicate and independently (SD, MP). Second, both reviewers compared their list of relevant studies and in the case of any disagreement the opinion of a third author was decisive (HZ). Third, full texts of potentially relevant studies were retrieved or obtained. Fourth, the full texts were screened by two reviewers in duplicate and independently (SD, MP). They used standardized and piloted data extraction forms. Fifth, the reviewers compared their list with each other and in the case of any disagreement the opinion of a third author was decisive (HZ). In addition, a third author screened the list of relevant studies (HZ).
Based on these steps, studies were included for the review. We used the preferred reporting items for systematic reviews and meta-analyses (PRISMA) flowchart to visualize the selection of the included studies (see figure 1 ). Moreover, we provide a table with statements on excluded studies (overview available on request). Data extraction was performed by two authors in duplicate and independently (SD, MP). In case of any disagreement, the opinion of a third author was decisive (HZ). We used a modified data extraction and assessment template from the Cochrane Public Health Group (CPHG). Previous to the major data extraction process, the authors piloted the data extraction form to ensure a standardized extraction. We extracted general information (publication type, country of study, funding source of study, potential conflict of interest from funding), study characteristics (type of study, participants, type of intervention, duration of intervention, type of control, and type of outcome measures, and other relevant information).
Assessment of risk of bias in included studies
The risk of bias of every included study was evaluated by two authors in duplicate and independently (SD, MP). In the case of any disagreement, the opinion of a third author was decisive (SL).
We used the Quality Assessment Tool for Quantitative Studies, based on the Effective Public Health Practice Project (EPHPP) Guidelines. To judge the risk of bias according to the Quality Assessment Tool for Quantitative Studies, the following three categories were used: 'strong', 'moderate', and 'weak' (Jackson and Waters 2005) .
We a priori considered unit of analysis issues, how to deal with missing data, assessment of heterogeneity, assessment of reporting bias, data synthesis, subgroup analysis, and sensitivity analysis. As we did not perform meta-analyses, there is no need to further deepen these methodological approaches in this context. However, details are outlined in the review protocol (Dreger et al 2015) .
Assessment of the quality of evidence
We provided a 'GRADE evidence profile' table (The Cochrane Collaboration 2011) (appendix C). This table includes information on the outcomes, the study design, the relative and absolute effect, the number of patients/participants, the number of studies included, the quality assessment, and the overall quality of evidence. Figure 1 shows the amended PRISMA flow diagram of study selection. Out of 2260 initially identified records, we determined that 58 were potentially relevant for full text assessment. After screening the full texts, four studies fulfilled the inclusion criteria.
Results
Description of studies
We excluded the remaining 54 for the following reasons: there were eight clinical experimental studies, four simulation studies, five dosimetry studies, eleven papers categorized as note, editorial, dossier or policy review, eight overview papers on KI administration and distribution, two papers with missing outcomes, two papers with missing interventions, and 14 papers on KI usage in Poland after Chernobyl (in the Polish language, screened by a native speaker) that did not meet the inclusion criteria, mostly because no data or selective results were reported. An overview of all excluded studies is available on request.
3.1.1. Study design. Of the four included studies, two studies are case-control studies (Cardis et al 2005 , Bandurska-Stankiewicz et al 2010 , one study is an analytic cohort (Brenner et al 2011) , and one study is a cross-sectional study (Zarzycki et al 1994) . All studies are related to the Chernobyl accident. The case-control studies had 1576 and 886 participants, respectively (Cardis et al 2005 , Bandurska-Stankiewicz et al 2010 . In the larger case-control study, the participants were younger than 15 years and in the smaller one, the participants were between 0 and 85+ years. In the analytic cohort study, 12 514 participants younger than 18 years were involved. The cross-sectional study had 1457 participants in the age range of 6-55 years (Zarzycki et al 1994) .
Interventions.
In all studies, some subjects received KI in the form of iodine prophylaxis (Zarzycki et al 1994) , potassium iodine as antistrumin (Cardis et al 2005) or Lugol's solution (Brenner et al 2011) . Although one study mentions that some participants repeated KI intake and some participants took KI during the five days following the nuclear accident, whereas others received KI later, differences in the health effects according to dosage and timing were not investigated (Zarzycki et al 1994) . The reports on the studies by Cardis et al (2005) and Brenner et al (2011) do not allow a clear-cut differentiation as to whether KI was taken only after the accident, or possibly as a goiter prophylaxis even before the accident. No details on intake levels around the time of the accident were provided. I.e. a tablet of the reported agent (antistrumin = KI) usually contains 0.5-1 mg of KI, so that thyroid blocking could only be achieved with the intake of multiple tablets to reach the necessary amount of a 30-130 mg dose in adults. Iodine prophylaxis against endemic goiter, however, is usually performed with doses that are two to three magnitudes lower.
3.1.4. Outcomes. Thyroid cancer was generally defined as histologically confirmed cancer that was diagnosed after clinical and laboratory findings during screening examinations. 
Risk of bias in included studies
The methodological quality summary based on the EPHPP quality assessment tool is summarized in figure 2.
We a priori considered allocation concealment and blinding of participants and outcomes for RCT as outlined in the protocol. Withdrawals and losses to follow-up were described only by one study (Brenner et al 2011) . None of the studies mentioned an intention-to-treat analysis. Selective reporting is not likely to have occurred as studies reported both significant and non-significant results.
Other potential sources of bias might be levels of KI administration and levels of exposure to radioactive iodine: As indicated, only the two studies with separate study populations from Poland focused on a post-accident KI intervention, while the other two studies reported on iodine prophylaxis without further detail, but with potentially much lower KI doses than required for thyroid blockage, as explained earlier. In all the studies, timing, exact dosage of KI administration (quantity and repetition) and levels of exposure to radioactive iodine were not clear. Therefore, the results might be biased by timing and dosage of KI administration and by levels of radioactive iodine exposure.
Effects of interventions
The effects of KI administration on ATMA, TGAb (Zarzycki et al 1994) Zarzycki et al (1994) measured ATMA and TGAb. In the descriptive analysis they did not find significant differences between adult participants who took KI and the control group. Prevalence rates for ATMA were 13% in the KI group and 14% in the control group. Prevalence rates for TGAb were 10% in the KI group and 13% in the control group. Calculating the relative risk resulted in an OR of 0.92 (95% CI 0.56-1.50) for ATMA and OR 0.74 (95% CI 0.43-1.27) for TgAB. The size of the children subgroup was too small to compare the effects of KI on ATMA and TGAb. In general, the study population was too small to run multivariate analyses. (2010) did not find significant differences in intake of KI in those who were diagnosed with cancer compared to the control group. Of the case patients with thyroid cancer, 31% had taken KI, while in the control group, 34% had taken KI. The respective OR was calculated as 0.87 (95% CI 0.65-1.18) for thyroid cancer after KI intake. Brenner et al (2011) investigated the effect modification of the excess relative risk (ERR) of incident thyroid cancer per Gy of exposure according to KI intake. The effect modification was not significant (p = 0.56), with an ERR Gy −1 of 2.11 (95% CI 0.36-9.28) for no KI administration and an ERR Gy −1 of 1.03 (95% CI 0.08-9.84) for KI administration. Based on data given per person years, we calculated the unadjusted relative effect of thyroid cancer after KI intake, resulting in an OR of 0.68 (95% CI 0.36-1.28). Cardis et al (2005) reported a statistically significant threefold reduction (OR adj 0.31, 95% 0.1-0.9) in the odds of thyroid cancer at 1 Gy in the group who took KI (possibly at rather low doses) compared to the reference group. This low OR was independent of soil iodide content in the respective area of residence. Based on data provided from the study authors, a simple case-control analysis in RevMan 5.3 resulted in an OR of 0.38 (95% CI 0.20-0.70).
Anti-human thyroid membrane antibodies and anti-thyreoglobulin antibodies.
Discussion
Summary of main results
Expectedly, we did not find a randomized controlled trial relating to our study question. We included two case-control studies, an analytic cohort and one cross-sectional study. In total, the studies included did not assess all of the outcomes we considered important a priori. Thus, we cannot report on the effect of KI in the case of nuclear accident on two relevant outcomes, i.e. hypothyroidism and benign thyroid nodules. The studies identified as relevant did not allow extracting information on subgroups. We were not able to establish a dose-response relationship between KI intake and health outcomes as the studies did not assess different quantities and repeated intake of KI. Two studies reported non-significant results on the relationship between prophylactic KI and thyroid cancer. The confidence intervals were wide, but the studies showed a tendency of decreased risks of developing thyroid cancer if KI was administered. This tendency was supported by a significant result from one study in children on considerably reduced risks of thyroid cancer after KI intake, albeit at potentially lower doses than required for thyroid blockage. Low to very low-quality evidence suggests that KI intake following a nuclear accident may reduce the risk of thyroid cancer in children.
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Overall completeness and applicability of evidence
The overall evidence base for the effect of KI administration after exposure to radioiodine release is rather incomplete, with the majority of studies investigating the association between KI intake and the risk of thyroid cancer. The review included studies from different countries and regions. It becomes apparent that comparability of results across studies is difficult due to diverse magnitudes of exposure in the different geographical regions, which were not always controlled. However, the limited evidence available suggests that the administration of KI might reduce the risk of adverse health outcomes after accidental release of radioiodine.
The studies included in the review focused on children, adults or both. Children may be the most vulnerable population due to the increased absorption of radioiodine. It is noteworthy that considerable effects of KI intake on the risk of developing thyroid cancer in children younger than 15 years were reported from one study included in the review (Cardis et al 2005) , even if details of the KI administration and intake level remain uncertain.
The evidence base for outcomes was of very low to low quality. Key methodological limitations were control for confounding and the study design. Limitations in the study design and execution, as well as imprecision were major weaknesses for the outcomes (for details see appendix C).
Potential biases in the review process
We have performed an extensive literature research. However, there could be relevant gray literature and unpublished studies that we did not find during the search process, and therefore, did not consider in our review. We did, however, contact experts with specific overview of the publication landscape in Russian as well as in the Japanese language to help us identify potential data sources or regional data bases of relevance for our study question. However, no additional relevant information was obtained. Although we found studies from different geographical regions, our results might not apply to all countries and settings similarly, as levels of exposure might differ across geographical regions.
ATMA and TGAb are surrogates for the diagnosis of hypothyroidism. However, these antibodies are frequently detected in the general population not exposed to radioactive fallout. Therefore, results on ATMA and TGAb need to be interpreted with caution.
We are aware that experimental animal studies provide further valuable supporting evidence on the efficiency of thyroid blocking in preventing health-associated long-term consequences in the case of a nuclear accident. Our search strategy did not include animals as we focused on the effects in human populations for which the intervention is proposed; however, we highlight additional information from simulation studies, which might be considered equally informative.
Within and across studies, the timing and the quantity of KI intake was not specified, and therefore, the results might be biased in unknown ways.
Agreements and disagreements with other studies or reviews
This is the first systematic review on the effect of KI intake on thyroid cancer, hypothyroidism and benign thyroid nodules after a nuclear accident. Therefore, we cannot compare our results to other systematic reviews.
However, we found two simulation studies on the effect of KI on thyroid irradiation Becker 2000, Jang et al 2008b) . These studies suggest that KI is highly effective with regard to the prevention of radioiodine uptake when administered 48 h before and within two hours after exposure to radioiodine release. KI administration 48 h before exposure to radioiodine release results in an almost complete blocking of radioiodine uptake. However, the intake of KI 96 h before exposure to radioiodine release has no protective effect (Zanzonico and Becker 2000) . These studies report a protective effect of KI intake after exposure to radioiodine release. The simulation studies report that the intake of KI within two hours after exposure to radioiodine release results in a blocking effectiveness of ca. 80% Becker 2000, Jang et al 2008b) . The review authors consider this as important additional evidence.
Similarly, in the overall assessment of KI thyroid blocking (KITB), information on potential adverse effects should be included. We did not address this topic in the current systematic review, but an earlier review from our group found limited evidence for adverse effects. It was found that the intake of even comparatively high doses of KI did not result in serious adverse health outcomes in the exposed population groups. Severe reactions were rare and especially observed in individuals with pre-existing thyroid disorders and iodine sensitivity. Furthermore, the results suggested that adverse effects after KI administration may be more likely to occur in newborns and the elderly compared to other age groups (Spallek et al 2012) .
Implications for practice
The results of this review suggest that KI administration following a nuclear accident may reduce the risk of thyroid cancer after exposure to radioactive iodine, particularly in children. However, this judgement is based on a small number of studies that provide low or very lowquality evidence. There is no evidence on the outcomes on hypothyroidism and benign thyroid nodules. The risk of the occurrence of immunological effects (ATMA and TgAB) could be reduced when subjects take KI in the case of a nuclear accident. Significant results on the decreased risks of thyroid cancer after KI intake following the release of radioiodine are based on data in children. The dosage and timing of KI administration in the study on persons who were aged <18 years at the time of the Chernobyl accident (Cardis et al 2005) were not well defined, and KI was potentially used at low doses. Therefore, the results need to be interpreted with caution.
Implications for research
Further studies of good quality are necessary to provide a better evidence base for the effects of KI on health outcomes in the case of nuclear accident. These studies should also investigate the effects in subgroups, e.g. pregnant women. In addition, the dosage and the timing of the intervention seem to be relevant for the effectiveness of KI on thyroid blockage. Therefore, future research must consider the timing and dosage when investigating the effects of KI on health outcomes after the release of radioiodine. Hypothyroidism and benign thyroid nodules should be additional outcomes of interest in future research on the effectiveness of KI administration after a nuclear accident. Conducting experimental studies with regard to these outcomes does not appear to be feasible due to ethical reasons.
Given that research on long-term intervention effects is possible only in the context of a-hopefully not-occurring-large-scale release of radionuclides, the verification of KITB effectiveness in experimental studies, such as randomized trials, is not conceivable, as the exposure generally constitutes an emergency situation. Nevertheless, in order to Review R124 obtain population-based evidence on the effectiveness, research planning is necessary. Considerations on how to include research components into emergency management plans for nuclear accidents might be a first step. Generally, an individualized radiation exposure assessment, coupled with specific information on KI intake, and a system for long-term follow-up of health effects would be needed to gain more reliable, cohort-based data on KITB effectiveness. Perhaps modern mobile communication technology could play an increasing role in planning and conducting such research in emergency situations, even though the vulnerability of ICT systems in disaster situations needs to be taken into account. 2B ("ITB" OR "iodine thyroid blocking" OR "potassium iodide" OR "Iodine Radioisotope * " OR "KI" OR "sodium iodide" OR ((blockade * OR blocking OR administration) AND iodine) OR "stable iodine" OR ((prophylaxis OR prophylactic * OR "prophylactic agent * ") AND (iodine * OR iodide * ))) 
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Block 2: Intervention(s)
Summary and results
Search name (saved in PubMed & EndNote) Results 1 AND 2 AND 3 1.321 1 AND 2 AND 3 (AND) NOT 4A 1.240 1 AND 2 AND 3 (AND) NOT 4B 1.225 1 AND 2 AND 3 (AND) NOT 4A (AND) NOT 4C 47 1 AND 2 AND 3 (AND) NOT 4B (AND) NOT 4C 47 1 AND 2 AND 3 (AND) NOT 4A AND 4D 1.038 1 AND 2 AND 3 (AND) NOT 4B AND 4D 1.023 3B (((Nuclear * or atomic or reactor * or radioactive * or radiation or radiological * ) and (accident * or warfare or contaminant * or exposure * or fallout or meltdown or disaster * or catastrophe * )) or ((Belarus or Chernobyl or Chornobyl or Hiroshima or Fukushima or Gomel or Homel or Ukraine or Minsk or "3 mile" or "three mile" or Nagasaki or Pripyat or Poland or Russia or USSR or "Soviet Union" or Japan) and (accident * or warfare or contaminant * or exposure * or fallout or meltdown or disaster * or catastrophe * ))).mp. 
Appendix C. GRADE evidence profile
Is the administration of KI preferable to no treatment in people exposed to radioiodine release in the environment to reduce the risk of thyroid cancer, hypothyroidism and benign thyroid nodules? Cross-sectional study Serious concern a No serious concern
No serious concern Very serious concern b,c None 22/169 (13.0) 114/816 (14.0) OR 0.92 (0.56-1.50) 10 fewer per 1000 (from 70 fewer to 50 more)
Very low
TGAb 1 Cross-sectional study Serious concern a No serious concern
No serious concern Very serious concern b,c None 17/169 No serious concern No serious concern No serious concern Serious concern b None 12/ 18 154 Serious concern d
No serious concern Serious concern b None 104/445 The absolute effect is based on the risk difference between the baseline of the control and the intervention group. 
